46
Trials as lead sponsor
Most active programmes
The drugs appearing most often across Insmed's recently active trials. Comparator arms are excluded.
- Brensocatib10 trials
- Treprostinil Palmitil Inhalation Powder6 trials
- Treprostinil Palmitil5 trials
- ALIS2 trials
- Azithromycin2 trials
- Ethambutol2 trials
Upcoming readouts
Next primary completion dates among Insmed's active phase 2 and phase 3 trials. Dates are registry estimates and move often, which is exactly what the tracker watches.
Top therapeutic areas
Conditions studied most often across Insmed's recently active trials.
- Cystic Fibrosis7 trials
- Pulmonary Arterial Hypertension5 trials
- Pulmonary Hypertension4 trials
- Mycobacterium Infections, Nontuberculous4 trials
- Interstitial Lung Disease3 trials
- Non-Cystic Fibrosis Bronchiectasis3 trials
Insmed trials
The 46 most significant of Insmed's recently active trials, soonest estimated readout first.
Select any row for the full record; the change timeline unlocks with tracking.
| Trial | Phase | Stability | Status | Enrollment | Est. readout |
|---|---|---|---|---|---|
| An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)NCT05649748Treprostinil Palmitil | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 91 est. | 31 Dec 2026 |
| A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Normal Hepatic Function and Participants With Hepatic ImpairmentNCT07643155Treprostinil Palmitil Inhalation Powder | Phase 1 | Not yet scored | OngoingNot yet recruiting | 30 est. | 7 Feb 2027 |
| PALM-PAHA Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)NCT07481981Treprostinil Palmitil Inhalation Powder | Phase 3 | Locked · track to reveal | OngoingRecruiting | 344 est. | 28 Dec 2028 |
| PALM-ILDEfficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)NCT07179380Treprostinil Palmitil Inhalation Powder | Phase 3 | Locked · track to reveal | OngoingRecruiting | 344 est. | 30 Dec 2028 |
| An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)NCT07234032Treprostinil Palmitil Inhalation Powder | Phase 3 | Locked · track to reveal | OngoingNot yet recruiting | 344 est. | 22 Jan 2031 |
| An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)NCT05649722Treprostinil Palmitil Inhalation Powder | Phase 2 | Locked · track to reveal | Completed | 31 est. | 1 Apr 2026 |
| CEDARA Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)NCT06685835Brensocatib | Phase 2 | Locked · track to reveal | StoppedTerminated | 214 est. | 12 Feb 2026 |
| ENCOREStudy to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium ComplexNCT04677569ALIS | Phase 3 | Locked · track to reveal | Completed | 425 est. | 21 Nov 2025 |
| A Study to Assess the Relative Bioavailability After a Single Inhalation Administration of Treprostinil Palmitil Inhalation Powder (TPIP) Formulation 2 (F2) to TPIP Formulation 3 (F3) in Healthy ParticipantsNCT07102316TPIP F2 | Phase 1 | Locked · track to reveal | Completed | 42 est. | 25 Oct 2025 |
| BiRChA Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)NCT06013241Brensocatib | Phase 2 | Locked · track to reveal | Completed | 288 est. | 30 Sept 2025 |
| A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial HypertensionNCT05147805Treprostinil Palmitil | Phase 2 | Locked · track to reveal | Completed | 102 est. | 27 Mar 2025 |
| ASPENA Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis BronchiectasisNCT04594369Brensocatib 10 mg | Phase 3 | Locked · track to reveal | Completed | 1,767 est. | 28 Oct 2024 |
| INS1007A Study to Assess the Relative Bioavailability of Brensocatib Pediatric Oral Solution to Oral Tablets in Healthy ParticipantsNCT06344728Brensocatib Oral Solution | Phase 1 | Locked · track to reveal | Completed | 24 est. | 24 May 2024 |
| A Study to Evaluate the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung DiseaseNCT05176951Treprostinil Palmitil | Phase 2 | Locked · track to reveal | Completed | 39 est. | 14 Mar 2024 |
| A Study of the Palatability and Acceptability of Different Brensocatib Oral Liquid Formulations in Healthy ParticipantsNCT06178783Brensocatib | Phase 1 | Locked · track to reveal | Completed | 20 est. | 4 Jan 2024 |
| A Study to Investigate Effect of Clarithromycin, a Strong CYP3A4 Inhibitor, on Brensocatib Pharmacokinetics in Healthy ParticipantsNCT05965570Brensocatib | Phase 1 | Locked · track to reveal | Completed | 22 est. | 22 Sept 2023 |
| A Study to Assess Pharmacokinetics (PK) of Brensocatib Alone and With Multiple Doses of Rifampin or Esomeprozole in Healthy ParticipantsNCT05826574Brensocatib | Phase 1 | Locked · track to reveal | Completed | 32 est. | 16 Jul 2023 |
| A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Brensocatib in Participants With Normal Hepatic Function and Participants With Hepatic ImpairmentNCT05517525Brensocatib | Phase 1 | Locked · track to reveal | Completed | 30 est. | 1 Jun 2023 |
| ARISEValidation of Patient Reported Outcome Measures in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium ComplexNCT04677543ALIS | Phase 3 | Locked · track to reveal | Completed | 99 est. | 9 May 2023 |
| A Study of Brensocatib Following a Single Oral Administration in Participants With or Without Renal ImpairmentNCT05673603Brensocatib | Phase 1 | Locked · track to reveal | Completed | 28 est. | 14 Feb 2023 |
| A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic FibrosisNCT05090904Brensocatib | Phase 2 | Locked · track to reveal | Completed | 29 est. | 1 Nov 2022 |
| A Study to Investigate the Effects of Brensocatib on QT Interval in Healthy ParticipantsNCT05355935Brensocatib | Phase 1 | Locked · track to reveal | Completed | 48 est. | 7 Oct 2022 |
| A Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH)NCT04791514Treprostinil Palmitil | Phase 2 | Locked · track to reveal | StoppedTerminated | 1 est. | 26 Aug 2022 |
| A Study of the Absorption, Metabolism, and Excretion of [14C]-Brensocatib Following a Single Oral Administration in Healthy Male ParticipantsNCT05652257[14C]-brensocatib | Phase 1 | Locked · track to reveal | Completed | 7 est. | 14 Sept 2021 |
| A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder (TPIP) in Healthy ParticipantsNCT06091579Treprostinil Palmitil Inhalation Powder | Phase 1 | Locked · track to reveal | Completed | 42 est. | 12 Jan 2021 |
| Assessment of INS1007 in Participants With Non-Cystic Fibrosis BronchiectasisNCT03218917Brensocatib 10 mg | Phase 2 | Locked · track to reveal | Completed | 256 est. | 12 Dec 2019 |
| A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of INS1007 in Healthy Japanese and Caucasian ParticipantsNCT05927597INS1007 | Phase 1 | Locked · track to reveal | Completed | 82 est. | 1 Aug 2019 |
| Open-label Safety Extension Study Assessing Safety and Tolerability of LAI in Patients Who Participated in Study INS-212NCT02628600LAI 590 mg | Phase 3 | Locked · track to reveal | Completed | 163 est. | 17 Oct 2018 |
| CONVERTStudy to Evaluate Efficacy of LAI When Added to Multi-drug Regimen Compared to Multi-drug Regimen AloneNCT02344004LAI (Liposomal Amikacin for Inhalation) 590 mg | Phase 3 | Locked · track to reveal | Completed | 336 est. | 3 Jul 2018 |
| A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of C16TR for Inhalation With Tyvaso® Cohort in Healthy ParticipantsNCT06193031C16TR | Phase 1 | Locked · track to reveal | Completed | 24 est. | 18 Dec 2015 |
| Extension Study of Liposomal Amikacin for Inhalation in Cystic Fibrosis (CF) Patients With Chronic Pseudomonas Aeruginosa (Pa) InfectionNCT01316276Liposomal amikacin for inhalation | Phase 3 | Locked · track to reveal | Completed | 206 est. | 16 Jul 2015 |
| Liposomal Amikacin for Inhalation (LAI) for Nontuberculous MycobacteriaNCT01315236Liposomal amikacin for inhalation (LAI) | Phase 2 | Locked · track to reveal | Completed | 90 est. | 18 Aug 2014 |
| Study to Evaluate Arikayce™ in CF Patients With Chronic Pseudomonas Aeruginosa InfectionsNCT01315678Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer. | Phase 3 | Locked · track to reveal | Completed | 302 est. | Jun 2013 |
| Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKAYCE™) - Extension PhaseNCT03905642Arikayce™ | Phase 2 | Locked · track to reveal | Completed | 49 est. | 2 Nov 2010 |
| Safety/Tolerability Study of Arikayce™ in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas AeruginosaNCT00558844Arikayce™ 560 mg | Phase 1 | Locked · track to reveal | Completed | 41 est. | Jun 2009 |
| Safety and Tolerability Study of 2 Dose Level of Arikayce™ in Patients With Bronchiectasis and Chronic Infection Due to Pseudomonas Aeruginosa.NCT00775138280 mg Arikayce™ | Phase 2 | Locked · track to reveal | Completed | 64 est. | 11 May 2009 |
| Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1NCT00577577rhIGF-I/rhIGFBP-3 | Phase 2 | Locked · track to reveal | Completed | 69 est. | 29 Dec 2008 |
| Inhalation SLIT Cisplatin (Liposomal) for the Treatment of Osteosarcoma Metastatic to the LungNCT00102531Cisplatin liposomal | Phase 1 | Locked · track to reveal | Completed | 19 est. | Mar 2008 |
| Multidose Safety and Tolerability Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKACE™)NCT00777296ARIKACE™ | Phase 1 | Locked · track to reveal | Completed | 66 est. | 27 Feb 2008 |
| Single Dose Escalation Study of TR02 (Sustained Lipid Inhalation Technology [SLIT™] Amikacin) in Participants With Cystic Fibrosis (CF) Having Chronic Infections of Pseudomonas AeruginosaNCT06238856SLIT™ Amikacin | Phase 1 | Locked · track to reveal | Completed | 18 est. | 8 Feb 2005 |
| A Study to Investigate Lung Deposition of Inhaled Amikacin-loaded Liposomes in Healthy Male ParticipantsNCT05999942Liposomal Amikacin for Inhalation | Phase 1 | Locked · track to reveal | Completed | 6 est. | 29 Jun 2004 |
| IGF-I/IGFBP-3 Therapy in Children and Adolescents With Growth Hormone Insenitivity Syndrome (GHIS) Such as Laron SyndromeNCT00368173rhIGF-I/rhIGFBP-3 | Phase 2 | Locked · track to reveal | Completed | — | — |
| Study to Evaluate Arikace™ in CF Patients With Chronic Infection Due to Pseudomonas AeruginosaNCT01315691Liposomal amikacin for inhalation | Phase 3 | Locked · track to reveal | StoppedWithdrawn | 0 est. | — |
| Research Study Using Recombinant Human Insulin-Like Growth Factor-1/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 for Children With Noonan SyndromeNCT00351221rhIGF-1/rhIGFBP-3 | Phase 2 | Locked · track to reveal | StoppedTerminated | 24 est. | — |
| An Expanded Access Study to Assess Treprostinil Palmitil Inhalation Powder (TPIP) for Participants With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)NCT06939647Treprostinil Palmitil | — | Not yet scored | Unknown | — | — |
| An Expanded Access Study to Assess Brensocatib for Participants With Non-Cystic Fibrosis BronchiectasisNCT05344508Brensocatib | — | Not yet scored | Unknown | — | — |